BioMarin Pharmaceutical Debt/Equity Ratio 2010-2024 | BMRN

BioMarin Pharmaceutical debt/equity ratio for the quarter ending September 30, 2024 was 0.11.

  • BioMarin Pharmaceutical average debt/equity ratio for 2023 was 0.18, a 25% decline from 2022.
  • BioMarin Pharmaceutical average debt/equity ratio for 2022 was 0.24, a 4% decline from 2021.
  • BioMarin Pharmaceutical average debt/equity ratio for 2021 was 0.25, a 0% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

BioMarin Pharmaceutical Debt/Equity Ratio 2010-2024 | BMRN

  • BioMarin Pharmaceutical average debt/equity ratio for 2023 was 0.18, a 25% decline from 2022.
  • BioMarin Pharmaceutical average debt/equity ratio for 2022 was 0.24, a 4% decline from 2021.
  • BioMarin Pharmaceutical average debt/equity ratio for 2021 was 0.25, a 0% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.